Manhattan BioSolutions, Inc.

Manhattan BioSolutions Initiates NCI PIVOT Collaboration in Pediatric Cancers NEW YORK?-?Jan. 30, 2025?-?PRLog?-- Manhattan BioSolutions, Inc. ("MABS"), an emerging biotechnology company developing new classes of precision biologics that harness natural host defense mechanisms, today announced that its RNA-targeting therapeutic, MABS-139, will be evaluated in pediatric cancer models through the National Cancer Institute (NCI) Pediatric Preclinical in Vivo Testing (PIVOT) Program. The PIVOT consortium, coordinated by The Jackson Laboratory, brings together leading pediatric cancer research centers to systematically evaluate promising therapies using extensively characterized patient-derived xenograft models. The studies with MABS-139 will be conducted at the University of Texas Health Science Center San Antonio, one of the PIVOT participating institutions. The collaboration, formalized through a Material Transfer Agreement with NCI, involves a two-phase research plan. In the first phase, PIVOT investigators will conduct tolerability study to confirm the dosing regimen. In the second phase, comprehensive efficacy testing will be conducted utilizing patient-derived xenograft models of pediatric cancers including Ewing sarcoma, malignant rhabdoid tumor, rhabdomyosarcoma, and hepatoblastoma. The research plan employs PIVOT's innovative single mouse trial design to efficiently evaluate anti-tumor activity. "Participation in the NCI PIVOT Program provides an extensive and invaluable level of expertise in preclinical pediatric cancer testing, and we are excited that MABS-139 was selected for evaluation after a diligent review process," said Dr. Borys Shor, CEO of Manhattan Bio. "Our novel agent degrades cancer-associated RNA which plays a fundamental role in promoting tumor growth, metastasis and resistance to current therapies. We are actively exploring this approach alongside other innovative payloads in our ADC development programs. This collaboration could potentially support a path to a rare disease pediatric voucher while generating valuable insights about addressing aggressive childhood cancers with limited treatment options." https://lnkd.in/eshsiGkZ

Honored to have attended the prestigious #GalienForum2024 The Galien Foundation last Thursday at Alexandria Center for Life Science, NYC! Sharing some snapshots from this inspiring event including our Manhattan Biosolutions team. Highlights included a dynamic fireside chat between Noubar Afeyan (Founder & CEO, Flagship Pioneering; Co-founder & Chairman, Moderna) and Michael Rosenblatt (Advisory Partner, Ascenta Capital), and an outstanding Big Biotech panel chaired by Nobel Laureate Dr Phillip Sharp (MIT) featuring george yancopoulos (President & CSO, Regeneron), Ray Deshaies, Ph.D. (SVP Global Research Emeritus, Amgen), Pushkal Garg (CMO, Alnylam), and Jane Grogan (EVP & Head of Research, Biogen). The exciting mRNA vs. Gene Therapy discussion was led by Mikael Dolsten (CSO & President, Pfizer R&D). Congratulations to all Prix Galien 2024 award winners, including Daiichi Sankyo US & AstraZeneca (ENHERTU?), Pfizer (PAXLOVID?), Immunocore (KIMMTRAK?), and others for their groundbreaking innovations in advancing global healthcare! Other fascinating panels covered: - Women's Health & Generational Health - Climate Change's Impact on Global Health - Immunology & Inflammation as cornerstones of disease treatment Looking forward to next year's forum! #Healthcare #Innovation #LifeSciences #Biotech #PrixGalien2024 Borys S. John Psaltos G. JOHN MOHR Agnes Westelinck Zev Gechtman William Johnson L. Nathan Tumey Dhaval Shah David Y. Ronald T. Raines

Honored that our CEO, Dr. Borys Shor was invited to join this year's exclusive JLABS Global CEO Summit 2024 at the New York Stock Exchange NYSE - an outstanding gathering of biotech innovators for two transformative days of insights and connections. The summit featured an intensive IPO Bootcamp and expert discussions on biopharma deals and funding landscape. A particular highlight was the inspiring keynote from Robert Langer, whose insights continue to shape the future of drug delivery and bioengineering. Special thanks to our hosts at the NYSE and to all the leading investors, dealmakers, and market experts who shared crucial?insights on capital markets and IPO preparation during the intensive IPO Bootcamp sessions. The evening reception on the trading floor was a perfect setting for meaningful conversations across the biotech ecosystem. We're incredibly grateful to Johnson & Johnson Innovation - JLABS for putting together this world-class event and including Manhattan BioSolutions, Inc. in this remarkable community. As a proud JLABS resident, and two-time QuickFire Challenge winner,?we're excited to keep pushing boundaries in next-generation targeted therapies. Melinda Richter Tingting Zhang-Kharas, PhD Tara Dziedzic Bonnie Hyun Eric J. Dimise, PhD Sharon Chan John Choi Sophie Shen, PhD, CFA #Biotech #Innovation #JLABS #NYSE

Manhattan BioSolutions, Inc. is thrilled to be featured in Binghamton University's latest news story, highlighting our groundbreaking collaboration with Dr. Nathan Tumey's lab and the NIH/NCI! The article, "Binghamton pharmacy professor grateful for research grants, partnerships to improve drug delivery technology," showcases our joint efforts in advancing next-generation ADC technology for both pediatric and adult cancers. Our partnership is revolutionizing targeted therapy with: - Innovative protease-activated linker technology designed to enhance tumor selectivity - Strategies aimed at improving safety profiles due to reduced off-target effects - Potential for higher therapeutic index in clinical applications This precision approach could be a game-changer, allowing for more aggressive dosing while minimizing systemic exposure - a critical advancement for both young and adult patients. We're proud to collaborate with L. Nathan Tumey and Dr. Javed Khan's team at the NIH/NCI. This synergy of academia, industry, and government expertise is accelerating the development of potentially transformative cancer treatments. Dive into the full story to explore how we're working to reshape the landscape of cancer therapy: https://lnkd.in/e6TzKk7R #ADC #Biotech #Oncology #BinghamtonUniversity #Innovation

Exciting breakthrough in ADC technology! ???? Congratulations to our scientific advisor, Dr. L. Nathan Tumey, and his team on their groundbreaking paper accepted for publication in Xenobiotica, titled "A comparison of the activity, lysosomal stability, and efficacy of legumain-cleavable and cathepsin cleavable ADC linkers"! This new work builds upon Dr. Tumey's pioneering 2021 study on legumain-cleavable linkers, further advancing the field of antibody-drug conjugates. Key highlights from this soon-to-be-published work: - Direct comparison of lysosomal cleavage, cytotoxicity, plasma stability, and efficacy of legumain-cleavable vs. cathepsin-cleavable ADCs - Demonstration that Asn-containing linker sequences are specifically cleaved by lysosomal legumain - Asn-linked MMAE ADCs show broad activity against various tumors, even those with low legumain expression - AsnAsn-linked ADCs exhibit comparable or improved efficacy to traditional ValCit-linked ADCs 1) This innovative approach addresses longstanding challenges in ADC development: 2) Enhanced stability in circulation while maintaining efficient payload release in lysosomes 3) Improved physicochemical properties through more hydrophilic peptide linker sequences 4) Potential for broader therapeutic application across tumor types with varying protease expression The implications for the ADC field are significant. This technology could enable more effective and safer targeted cancer therapies by overcoming limitations of traditional cathepsin-cleavable ADC designs, particularly issues related to premature linker cleavage and clearance due to linker hydrophobicity. At Manhattan BioSolutions, we're proud to be advancing next-generation ADCs incorporating legumain-cleavable linkers. Our proprietary platform builds upon this cutting-edge research, combining advanced linkers with potent TOP1i payloads to create ADCs with improved therapeutic index. We're excited to translate these scientific advancements into potential new treatment options for patients with hard-to-treat cancers. Potential partners or investors interested in our innovative LEG-TOP1i technology are welcome to reach out to us to explore collaboration opportunities. #ADCs #cancer #innovation #biotech

Manhattan BioSolutions Partners to Advance Taxoids as Innovative ADC Payloads https://lnkd.in/giyVTk7w

Last week, on May 21, 2024, we were honored to have been selected as one of the few companies invited to present at the Mansfield Bio-Incubator event, which featured a diverse range of innovative life sciences companies. Our Scientific Director, Zev Gechtman, showcased Manhattan Bio' groundbreaking approach to cancer treatment using next-generation precision biologics that harness the power of host defense adaptations. The event brought together investors, entrepreneurs, mentors, life science professionals, business development experts, and sponsors to explore innovative healthcare solutions and investment opportunities across various sectors, including therapeutics, diagnostics, medical devices, and biotechnology. Notable speakers included Christopher McDermott, Economic Development Manager for the Town of Mansfield; Massachusetts House Representative Jay Barrows, State Rep from the 1st Bristol District; and Sarah Stanton, the Undersecretary of Economic Strategies from the Executive Office of Housing and Economic Development (EOHED) for the Commonwealth of Massachusetts. We are grateful to the Mansfield Bio-Incubator, especially Alex Shlyankevich and Alexander Margulis, Ph.D., for recognizing the potential of Manhattan BioSolutions, Inc. Bio and providing us with this exceptional opportunity to showcase our work as we continue our mission to revolutionize cancer treatment. #innovation #beatcancer #ADCs #RNA

Impressive turnout at the EF Hutton Annual Global Conference yesterday, held at the iconic Plaza Hotel in NYC. It was a great opportunity for executives and investors to connect. Insightful discussions on SPACs, successful transactions, and micro-cap IPOs. The Edwardian Room was the perfect spot for the post-conference social #biotech #investments #nyc #IPOs

The Manhattan BioSolutions, Inc. team was honored to attend an exclusive event organized by SternAegis Ventures & Aegis Capital Corp. at the RT60 Rooftop Bar & Lounge, located on the 34th floor of the Hard Rock Hotel New York. This invitation-only reception brought together top professionals from the biotech, finance, and investment communities in the heart of Times Square. #biotech #innovation Borys S. Jenny Maharjan, MBA, B.Pharm John Psaltos William Johnson G. JOHN MOHR

Manhattan BioSolutions, Inc. had an incredible experience at the 2024 JLABS Investor & Partnering Day, held at the New York Genome Center, home of JLABS@NYC. This expertly curated event brought together innovative biotech startups and investors from the US North East region. A special thanks to the Johnson & Johnson Innovation JLABS team, including Scott Shepherd, Miriam Huber, Tingting Zhang-Kharas, PhD, and Jesse Hwang, for their tireless efforts in creating this impactful event. The expert speakers, including Marian Nakada, Ph.D., Katie Bodner Spielberg, Rachel Mears, and Pablo Lubroth, offered invaluable guidance on navigating the current fundraising environment. It was great to reconnect with Michal Preminger, Head of Innovation, East North America, Sharon Chan, VP of JLABS Asia Pacific, and Jun X., Executive Director - Therapy Acceleration Program Lead, The Leukemia & Lymphoma Society, after the event. We invite investors and collaborators to explore partnership opportunities with us as we work towards groundbreaking solutions in the biotech space. Thank you JLABS, for empowering the biotech startup ecosystem and facilitating meaningful connections that will shape the future of healthcare. (Pictured: Borys S. and Jenny Maharjan, MBA, B.Pharm from the Manhattan BioSolutions, Inc., team) #JLABS #biotech #innovation